Figure 7. Target knocking down RAD51AP1 inhibited the progression of the EGFRvIII-positive intracranial GBM model. (A) The tumor volumes at the indicated times were evaluated by bioluminescence imaging. (B) Survival rates of mice bearing U87-EGFRvIII and EGFRvIII-siRAD51AP1 tumors. (C) Immunohistochemistry analysis was performed to detect Ki-67 and CD34 expression.